Two candidate vaccines at the University of Oxford showed positive trial results Monday against the virus that causes COVID-19. This means it is more likely that a safe, effective vaccine can be developed quickly.
Two previous studies on different vaccine candidates also appeared to be relatively safe and triggered appropriate immune responses in study subjects, according to the AP.
Early stage trials only explore safety and dosing and cannot determine a vaccine’s effectiveness. The New York Post reported that signs indicate all four candidate vaccines are leading to immune responses.
There are currently about 17 candidate vaccines being tested in people around the world, according to the Daily Mail. The new results showed Oxford University and drug company Astra Zeneca’s candidate vaccine, AZD-1222, led to strong immune responses for nearly two months.
A second dose, given to 10 patients, seems to have boosted their immune response further, according to a paper published Monday. Half the volunteers were given the SARS-CoV-2 vaccine and half were given a meningitis vaccine.
This article is comprised of information and media from the AP, the New York Post, and the Daily Mail. For more sports, news and information follow the Midwest Sports Network on Twitter @MWSNsports or like the MWSN page on Facebook.
